© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Stroke Risk and Tamoxifen Therapy for Breast Cancer
Affiliations of authors: Research and Evaluation Department, Kaiser Permanente Southern California, Pasadena, CA (AMG, WC); Departments of Neurology (GMF) and Preventive Medicine (LB), Keck School of Medicine, University of Southern California, Los Angeles
Correspondence to: Ann M. Geiger, PhD, Research and Evaluation Department, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91188 (e-mail: ann.m.geiger{at}kp.org)
Background: Tamoxifen, which is used widely to treat, and increasingly to prevent, breast cancer, has been associated with increased risk of stroke. We assessed the impact of tamoxifen treatment for breast cancer on the risk of stroke, considering dose, duration, and recency of use of tamoxifen and known stroke risk factors. Methods: We conducted a nested case–control study of stroke after breast cancer among female Los Angeles County residents enrolled in a large health maintenance organization when diagnosed with breast cancer between January 1, 1980, and July 1, 2000. We obtained information on breast cancer treatment and stroke risk factors through medical record review and telephone interviews. The association (odds ratio [OR] and 95% confidence interval [CI]) between tamoxifen and stroke risk was determined by using a conditional logistic regression model, adjusting for menopausal status and history of hypertension and diabetes. All statistical tests were two-sided. Results: Of 11 045 women with breast cancer, 179 met stroke eligibility criteria and were individually matched to two stroke-free control subjects with breast cancer on age and year of breast cancer diagnosis. The mean age at breast cancer diagnosis was 66.6 years (standard deviation [SD] = 12.3 years), and the mean at-risk period (i.e., the time between breast cancer diagnosis and first stroke or comparable time period for control subjects) was 5.7 years (SD = 4.5 years). Tamoxifen use was not associated with risk of stroke, either overall (OR = 1.0, 95% CI = 0.6 to 1.6) or in subgroups defined by duration, dose, or recency of use. Chemotherapy, but not a specific chemotherapy regimen, was associated with an increased risk of stroke, regardless of tamoxifen use (no tamoxifen use, OR = 2.8, 95% CI = 1.3 to 6.3; tamoxifen use OR = 2.2, 95% CI = 1.2 to 4.1). Conclusions: Tamoxifen use is not associated with increased stroke risk. Further exploration of possible increased stroke risk following chemotherapy treatment for breast cancer is needed.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Chemotherapy, But Not Tamoxifen, Associated With Stroke Risk After Breast Cancer Treatment
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1487.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  R. K. Hernandez, H. T. Sorensen, J. Jacobsen, L. Pedersen, and T. L. Lash Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2509 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hooning, L. D.A. Dorresteijn, B. M.P. Aleman, A. C. Kappelle, J. G.M. Klijn, W. Boogerd, and F. E. van Leeuwen Decreased Risk of Stroke Among 10-Year Survivors of Breast Cancer J. Clin. Oncol., December 1, 2006; 24(34): 5388 - 5394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Earle Failing to Plan Is Planning to Fail: Improving the Quality of Care With Survivorship Care Plans J. Clin. Oncol., November 10, 2006; 24(32): 5112 - 5116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Perez Appraising Adjuvant Aromatase Inhibitor Therapy Oncologist, November 1, 2006; 11(10): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Barrett-Connor, L. Mosca, P. Collins, M. J. Geiger, D. Grady, M. Kornitzer, M. A. McNabb, N. K. Wenger, and the Raloxifene Use for The Heart (RUTH) Trial Inve Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med., July 13, 2006; 355(2): 125 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adess, R. Eisner, S. Nand, J. Godwin, H. L. Messmore Jr, and W. H. Wehrmacher Thromboembolism in cancer patients: pathogenesis and treatment. Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 254 - 266. [Abstract] [PDF]
|
|